MEDICAL RESEARCH | OCTOBER 26, 2026. What if two complementary therapies commonly discussed in palliative cancer care were linked to longer survival? A new prospective study from South Korea suggests a reason to investigate precisely that possibility. But a numerical association—even a statistically significant one—is not the same as evidence that an intervention actually caused people to live longer.
Published September 23, 2026, in the peer-reviewed journal Cancers, the paper “High-Dose Intravenous Vitamin C and Mistletoe Therapy in Breast Cancer: A Prospective Cohort Study on Overall Survival in Palliative Care” analyzed 748 female patients with breast cancer treated at a specialized center in Seoul. The authors, led by Donghun Lee and colleagues, observed an association between two adjunctive treatments—high-dose intravenous vitamin C and injected mistletoe extract—and lower mortality during follow-up. The study does not establish that either treatment prolongs life.
1. What the researchers actually studied
The investigators followed clinical records from the Yeom Chang Hwan Hospital in South Korea, spanning patients treated between April 2011 and May 2024. It was a prospective cohort study, not a randomized clinical trial. Patients received varying combinations of conventional cancer treatments and integrative or palliative interventions; decisions depended on clinical circumstances and patient preference. The research question was whether exposure to each complementary modality was associated with overall survival.
Patients with incomplete treatment records, fewer than three visits, or follow-up of 45 days or less were excluded, as were certain patients without usable follow-up data. Such eligibility choices can affect which patients remain in the analysis, particularly in a seriously ill population. This does not automatically invalidate the study, but it limits what can be inferred about all patients with advanced breast cancer.
The median follow-up was 10.0 months (interquartile range 2.9–30.2 months). The authors reported 109 deaths among 748 participants, or approximately 14.6%. The study assessed all-cause mortality rather than demonstrating tumor shrinkage or a specific anticancer mechanism.
2. The two therapies: high-dose IV vitamin C and mistletoe
Intravenous vitamin C: Patients received 10–100 grams of vitamin C intravenously once or twice weekly, according to the paper. The treatment definition required a specified minimum exposure history: at least three months and more than 10 sessions. Intravenous administration can produce blood concentrations quite different from oral vitamin C. That biochemical fact, however, does not by itself demonstrate a survival benefit in cancer patients.
Mistletoe extract: Patients received a commercially produced mistletoe preparation by subcutaneous injection, at doses of 0.02–20 milligrams, once or twice weekly, again with a defined course. This is not the same as consuming wild mistletoe or making an unregulated home preparation. Mistletoe preparations have been studied in some European integrative oncology settings, especially for symptoms and quality of life, but their effects on survival remain uncertain.
Both interventions were used alongside conventional oncology care, including surgery, chemotherapy, or radiotherapy where applicable. The paper provides no basis for claiming that vitamin C or mistletoe should replace established breast cancer treatments.
3. The numbers behind the headline
In the researchers’ multivariable, time-dependent statistical model, high-dose IV vitamin C was associated with an adjusted hazard ratio (HR) of 0.561 (95% confidence interval 0.319–0.986; p = 0.045). Mistletoe was associated with an HR of 0.463 (95% confidence interval 0.231–0.927; p = 0.030). Those are the central findings.
| Treatment | Adjusted hazard ratio | 95% confidence interval | p-value |
|---|---|---|---|
| High-dose IV vitamin C | 0.561 | 0.319–0.986 | 0.045 |
| Mistletoe extract | 0.463 | 0.231–0.927 | 0.030 |
| Hyperthermia | 1.497 | 0.794–2.820 | 0.212 |
An HR below 1 means the model estimated a lower instantaneous rate of death during the observed period for exposed patients than for the comparison group, after its adjustments. It does not mean that an individual patient’s chance of dying dropped by exactly 43.9% or 53.7%, nor does it establish the amount of additional life expectancy gained. Those percentages are mathematical descriptions of the fitted hazard ratios.
Both confidence intervals were relatively wide, and the IV vitamin C estimate narrowly met the conventional p < 0.05 threshold. The study evaluated multiple complementary modalities, so the findings need independent replication rather than an assumption that statistical significance settles the clinical question. Hyperthermia and several other treatments studied did not show a statistically significant association in the adjusted model.
4. Why the statistical design matters: immortal time bias
A particularly important problem in observational treatment research is immortal time bias. If the “treated” group is defined only after a patient survives long enough to complete months of therapy, those required survival months can falsely make treatment look protective.
The authors reported responding to this concern by modeling treatment as a time-dependent exposure: before a patient’s first treatment session, that person contributed time to the unexposed category; afterward, time was categorized as exposed. They also used Simon–Makuch survival curves and the Mantel–Byar test. Their published peer-review correspondence explicitly discusses revisions to address the bias. This is a meaningful methodological strength compared with simply labeling everyone as treated from enrollment.
It does not remove all sources of bias. The publication also describes minimum treatment-duration and session thresholds, and an observational model cannot make the clinical decisions surrounding therapy completely random. The relevant question is whether unmeasured differences between patients receiving and not receiving the therapies could explain some or all of the association.
5. The biggest uncertainty: were the patients comparable?
No investigator randomly assigned the 748 patients to receive vitamin C, mistletoe, or neither. People who chose or tolerated repeated appointments may have differed from other patients in overall condition, financial resources, functional status, cancer progression, access to other treatments, and motivation to seek additional care.
The paper reports that distant metastasis was present in 70.6% of participants who died, compared with 17.7% of survivors. Triple-negative disease and patterns of conventional treatment also differed. These are major predictors of prognosis, not small background details. The researchers adjusted for several of them, including age, metastatic status, triple-negative disease, surgery, chemotherapy, and radiotherapy.
But the authors acknowledged that detailed tumor (T) and lymph-node (N) staging had more than 40% missing data and was omitted from the multivariable model. Distant metastasis was used as an alternative stage indicator. That leaves important questions about remaining differences in disease severity, other therapies, and patient health. Statistical adjustment helps account for measured differences; it cannot reliably correct factors that were never adequately measured.
6. Did the therapies work together?
This paper analyzed associations for individual complementary modalities while accounting for other therapies. Its principal headline findings relate to separate associations for IV vitamin C and mistletoe. It does not demonstrate that combining them creates a synergistic effect or that the combination is superior to either therapy alone. Treating the two hazard ratios as proof of a powerful combined protocol would go beyond the evidence.
7. What about safety?
The investigators said they observed no severe treatment-related toxicities attributable to these therapies and no treatment-related deaths in the analyzed cohort. That observation is relevant but does not prove the treatments are universally safe or that adverse events were fully captured.
High-dose IV vitamin C can pose risks for people with certain conditions, including glucose-6-phosphate dehydrogenase (G6PD) deficiency and significant kidney problems; monitoring and potential treatment interactions require qualified clinical judgment. Mistletoe injections may cause local reactions, allergic reactions, fever, and other adverse effects. Neither should be treated as an ordinary dietary supplement merely because it originates from a vitamin or plant.
Patients receiving cancer treatment should discuss complementary interventions with their oncology team, including all drugs, kidney-function issues, and other health conditions. The study should not be used as a reason to stop chemotherapy, hormone therapy, radiation, targeted treatments, or other evidence-based care.
8. How this fits with larger cancer research
The U.S. National Cancer Institute has reviewed research on high-dose vitamin C and mistletoe extracts. Some investigations have explored quality of life, treatment symptoms, biological mechanisms, and potential anticancer effects. But the evidence is heterogeneous, with many studies too small, nonrandomized, or otherwise limited to prove that these therapies lengthen survival. Neither therapy is established as a substitute for standard oncologic treatment.
The South Korean cohort is therefore worth studying seriously without exaggerating it. It offers a clinical signal to test through rigorous randomized trials with standardized dosing, adequate measurement of cancer stage and treatment histories, careful adverse-event monitoring, and long-term survival outcomes.
9. What would it take to establish a real survival benefit?
A stronger test would randomly assign eligible patients to standard care with or without a carefully defined adjunctive treatment; track both groups from comparable starting points; document cancer subtype, stage, treatment, functional status, and co-interventions; and compare overall survival, symptom burden, quality of life, and safety. Ideally, trials would be large enough to detect meaningful effects reliably and replicate findings across hospitals and patient populations.
Researchers should also determine whether any effect depends on timing, dose, chemotherapy regimen, metastatic status, or the type of mistletoe preparation. Until then, patients and clinicians face an interesting hypothesis rather than a proven survival-extending intervention.
Apep Bar’s question: what should count as proof?
This study raises a question that deserves both openness and rigor. If a relatively inexpensive vitamin infusion or a botanical extract genuinely improves survival, patients deserve trials capable of showing it. If the association is produced by differences in who received treatment, patients equally deserve protection from claims that turn an uncertain finding into a promise.
Can integrative oncology research move beyond polarized arguments to produce the kind of evidence that allows patients to know what actually helps them live longer?
Question. Investigate. Reconsider.
Source documentation
Lee et al., Cancers, September 23, 2026, DOI: 10.3390/cancers18193094 · PubMed abstract and bibliographic record · Open peer-review reports and author responses · National Cancer Institute: High-Dose Vitamin C · National Cancer Institute: Mistletoe Extracts.
Editorial note: The article distinguishes adjusted observational associations from evidence of a causal survival benefit. This is research reporting, not individual medical advice. The clinical and botanical photographs are illustrations, not images of study participants or experimental procedures. No study participant is identified or depicted.
